

Complete this requisition for all international samples. Athena requires that international specimens be accompanied by payment in U.S. dollars. If pre-payment is not received, there will be a delay in result reporting.

Please call our Client Services Department at 00-1-508-756-2886, option 2 or contact us on our website at AthenaDiagnostics.com/international if you have questions regarding shipping or if you need further information.

Who Should Athena Contact with Questions About this Order?

Name _____
First Last
 Phone _____ Fax _____
 Email _____

Tests Ordered*

Check the test(s) required on the reverse **or** write in below.

Test Code _____ Test Name _____
 Test Code _____ Test Name _____

Payment Information

- Bank Check Enclosed (made payable to Athena Diagnostics, Inc.)
- Credit Card:
 - Visa Discover MC AMEX

Credit Card # _____
 Exp: _____ Security Code: _____
 Cardholder Name: _____
As it appears on card

Billing Address: _____

- Wire Transfer (Athena will send you wire transfer details.)
 Fax Number: _____
 E-Mail: _____

Testing will not begin until payment is received.

Laboratory Information

Lab Name _____

Complete Lab Address:

Phone _____ Fax _____

***Indicates required information**

Patient Identification

Patient Name* _____
First Last

DOB* _____ Sex: Male
 Female
 Unknown
 Age* _____

Patient ID # (if available) _____

Authorization to Use De-Identified Sample or Data for Research. To promote medical understanding and develop better health insights, Athena Diagnostics requests your permission to use your specimen in a de-identified way (without identifying information) for research, educational studies, commercial purposes and/or publication, if appropriate. Your name or other personal identifying information will not be used in or linked to the results of any studies and publications. Your refusal to have your specimen used or not used for research purposes will not affect processing or testing of your specimen, your test results or the service support provided by Athena Diagnostics to your physician. Please indicate your approval by checking the box next to **Yes** or denial by checking the box next to **No**.

I consent to the use of my de-identified specimen or data for research: Yes No

Signature of Patient, Parent or Legally Authorized Representative _____ Date _____

Printed Name of Patient, Parent or Legally Authorized Representative _____ Date _____

Relationship to Patient if Signatory is Someone Other than Patient _____

Authorized Result Report Recipients Required Physician Information

Name _____
First Last

Complete Mailing Address:

Indications for Testing (Check One)

- Diagnostic (symptomatic) Clinical Study Prenatal
- Predictive (asymptomatic) Carrier Other Research

Physician Attestation of Informed Consent

In accordance with Massachusetts General Law Chapter 111, Section 70G, and New York Civil Rights Law Section 79-1 verification of patient informed consent is required for genetic testing. Additionally, testing laboratories located in Massachusetts require a signed acknowledgement from the ordering medical practitioner. The signed acknowledgement is required to complete the genetic testing ordered if you have not previously signed a blanket Physician Attestation of Informed Consent (PAIC) at any Quest lab. The company offers a blanket PAIC that can be signed for all future orders.

I warrant that I have obtained both oral and written consent using the **Patient Informed Consent Form for Genetic Testing** provided by Athena Diagnostics. This written consent was signed by the person who is the subject of the test (or if that person lacks capacity to consent, signed by the person authorized to consent for that person).

Medical Practitioner Signature _____ Date _____

Printed Name of Medical Practitioner _____ NPI _____

Patient Informed Consent Form for Genetic Testing is available at AthenaDiagnostics.com/consent.

Type of Specimen **Date Collected*** _____

- Whole Blood Serum CSF Muscle Plasma DNA: Volume _____ Concentration _____

Once this form is complete, please ensure that you have:

- Verified the specimen type and included date of collection
- Verified that the Indications for Testing section has been completed by the physician

NOTE: Specimen tube(s) must be labeled with two of the following forms of identification: name, date of birth, patient ID no. These same two forms of ID should also be indicated on the test requisition.

Nephrology Patient Insurance Test Requisition (April 2015)

| Test Code | Test Name | Spec. | Min. Vol. | Tube Type |
|---|---|-------|-----------|-----------|
| Alport Syndrome | | | | |
| <input type="checkbox"/> 759 | Complete Alport Evaluation (COL4A3,4,5 DNA Sequencing; COL4A5 Deletion Test) | B | 20 mL | L |
| <input type="checkbox"/> 755 | COL4A5 DNA Sequencing and Deletion Test | B | 20 mL | L |
| <input type="checkbox"/> 756 | COL4A5 Deletion Test | B | 20 mL | L |
| <input type="checkbox"/> 757 | COL4A3 DNA Sequencing Test | B | 20 mL | L |
| <input type="checkbox"/> 758 | COL4A4 DNA Sequencing Test | B | 20 mL | L |
| Amyloidosis | | | | |
| <input type="checkbox"/> 235 | Amyloidosis Evaluation (TTR) | B | 20 mL | L |
| Bardet-Biedl Syndrome | | | | |
| <input type="checkbox"/> 887 | Bardet-Biedl Syndrome Evaluation (BBS1, BBS2, BBS10) | B | 10 mL | L |
| <input type="checkbox"/> 871 | BBS1 (BBS) DNA Sequencing Test | B | 10 mL | L |
| <input type="checkbox"/> 872 | BBS2 (BBS) DNA Sequencing Test | B | 10 mL | L |
| <input type="checkbox"/> 886 | BBS10 (BBS) DNA Sequencing Test | B | 10 mL | L |
| Fanconi Syndrome | | | | |
| <input type="checkbox"/> 517 | MELAS mtDNA Evaluation (MELAS 3243, 3271, 3252, 3256, 3291, 13513) | B | 20 mL | L |
| Family Testing | | | | |
| <input type="checkbox"/> 185 | Familial DNA Sequence Evaluation This test detects previously identified sequence variants in at-risk family members. Proband Accession # _____ Relationship _____ | B | 10 mL | L |
| Hereditary Renal Tubular Disorders | | | | |
| <input type="checkbox"/> 767 | Hereditary Renal Tubular Disorders Evaluation (SLC12A1, KCNJ1, CLCNKB, BSND, SLC12A3) | B | 10 mL | L |
| <input type="checkbox"/> 762 | SLC12A1 DNA Sequencing Test (Bartter type 1) | B | 10 mL | L |
| <input type="checkbox"/> 763 | KCNJ1 DNA Sequencing Test (Bartter type 2) | B | 10 mL | L |
| <input type="checkbox"/> 764 | CLCNKB DNA Sequencing Test (Bartter type 3) | B | 10 mL | L |
| <input type="checkbox"/> 765 | BSND DNA Sequencing Test (Bartter type 4) | B | 10 mL | L |
| <input type="checkbox"/> 766 | SLC12A3 DNA Sequencing Test (Gitelman) | B | 10 mL | L |
| <input type="checkbox"/> 825 | Autosomal Dominant Hypocalcemia (CASR) Evaluation | B | 10 mL | L |
| Monogenic Hypertension | | | | |
| <input type="checkbox"/> 749 | Monogenic Hypertension Evaluation (SCNN1B, SCNN1G, CYP11B1, HSD11B2) | B | 10 mL | L |
| <input type="checkbox"/> 747 | Liddle's Syndrome Evaluation (SCNN1B, SCNN1G) | B | 10 mL | L |
| <input type="checkbox"/> 748 | Pseudohypoaldosteronism Type 1 Evaluation (SCNN1A, SCNN1B, SCNN1G) | B | 10 mL | L |
| <input type="checkbox"/> 772 | SCNN1A DNA Sequencing Test | B | 10 mL | L |
| <input type="checkbox"/> 745 | SCNN1B DNA Sequencing Test | B | 10 mL | L |
| <input type="checkbox"/> 746 | SCNN1G DNA Sequencing Test | B | 10 mL | L |
| <input type="checkbox"/> 774 | CYP11B1 DNA Sequencing Test | B | 10 mL | L |
| <input type="checkbox"/> 775 | HSD11B2 DNA Sequencing Test | B | 10 mL | L |
| <input type="checkbox"/> 779 | CYP11B1/CYP11B2 Chimeric Gene Fusion Test | B | 10 mL | L |
| Nephrogenic Diabetes Insipidus | | | | |
| <input type="checkbox"/> 854 | Nephrogenic Diabetes Insipidus Evaluation (AVPR2, AQP2) | B | 10 mL | L |
| <input type="checkbox"/> 851 | AVPR2 DNA Sequencing Test | B | 10 mL | L |
| <input type="checkbox"/> 852 | AQP2 DNA Sequencing Test | B | 10 mL | L |
| Nephronophthisis | | | | |
| <input type="checkbox"/> 750 | NPH1 (Familial Juvenile Nephronophthisis (FJN)) Molecular Test | B | 10 mL | L |

| Test Code | Test Name | Spec. | Min. Vol. | Tube Type |
|----------------------------------|---|-------|-----------|-----------|
| Nephrotic Syndrome | | | | |
| <input type="checkbox"/> 722 | Early Onset Nephrotic Syndrome Evaluation (PLCE1, LAMB2, WTI, NPHS1, NPHS2) | B | 10 mL | L |
| <input type="checkbox"/> 717 | Inherited Focal and Segmental Glomerulosclerosis (FSGS) Evaluation (INF2, ACTN4, TRPC6, NPHS2) | B | 10 mL | L |
| <input type="checkbox"/> 711 | ACTN4 DNA Sequencing Test | B | 10 mL | L |
| <input type="checkbox"/> 712 | TRPC6 DNA Sequencing Test | B | 10 mL | L |
| <input type="checkbox"/> 716 | INF2 DNA Sequencing Test | B | 10 mL | L |
| <input type="checkbox"/> 718 | PLCE1 DNA Sequencing Test | B | 10 mL | L |
| <input type="checkbox"/> 713 | WTI DNA Sequencing Test | B | 10 mL | L |
| <input type="checkbox"/> 714 | LAMB2 DNA Sequencing Test | B | 10 mL | L |
| <input type="checkbox"/> 710 | NPHS2 DNA Sequencing Test (Steroid Resistant Nephrotic Syndrome; Podocin) | B | 10 mL | L |
| <input type="checkbox"/> 730 | NPHS1 DNA Sequencing Test (Congenital Nephrotic Syndrome; Nephrin) | B | 10 mL | L |
| Polycystic Kidney Disease | | | | |
| <input type="checkbox"/> 761 | Complete PKD Evaluation Step 1. PKD1/PKD2 Sequencing; Step 2. PKD1/PKD2 MLPA | | | |
| <input type="checkbox"/> 725 | PKDx DNA Sequencing Test (PKD1 and PKD2 Sequencing) | B | 10 mL | L |
| <input type="checkbox"/> 728 | PKDx Familial Mutation Evaluation (PKD1 and PKD2 Single Exon Sequencing) Proband Accession # _____ Relationship _____ | B | 10 mL | L |
| <input type="checkbox"/> 760 | PKD Deletion Test (PKD1/PKD2 MLPA) | B | 10 mL | L |
| Other Cystic Diseases | | | | |
| <input type="checkbox"/> 556 | Complete Tuberosus Sclerosis Evaluation (TSC1 Sequencing, TSC1 Deletion, TSC2 Sequencing, TSC2 Deletion) | B | 20 mL | L |
| <input type="checkbox"/> 521 | TSC1 DNA Sequencing Test | B | 20 mL | L |
| <input type="checkbox"/> 508 | TSC1 DNA Deletion Test | B | 20 mL | L |
| <input type="checkbox"/> 522 | TSC2 DNA Sequencing Test | B | 20 mL | L |
| <input type="checkbox"/> 523 | TSC Familial Mutation Evaluation (TSC1 and TSC2 Single Exon Sequencing) Proband Accession # _____ Relationship _____ | B | 10 mL | L |
| <input type="checkbox"/> 524 | TSC2 DNA Deletion Test | B | 10 mL | L |
| <input type="checkbox"/> 770 | Hereditary Interstitial Kidney Disease (2 exon UMOD seq.) | B | 10 mL | L |
| <input type="checkbox"/> 836 | TCF2 DNA Sequencing Test (Renal Cysts and Diabetes Syndrome (RCAD)) | B | 10 mL | L |
| Renal Cancer | | | | |
| <input type="checkbox"/> 889 | Pheochromocytoma Evaluation (RET, VHL, SDHB) | B | 10 mL | L |
| <input type="checkbox"/> 813 | MEN2 (RET) Evaluation | B | 10 mL | L |
| <input type="checkbox"/> 818 | MEN1 (MENT) Evaluation | B | 10 mL | L |
| <input type="checkbox"/> 888 | SDHB DNA Sequencing Test | B | 10 mL | L |
| <input type="checkbox"/> 858 | von Hippel-Lindau Syndrome (VHL) Evaluation | B | 10 mL | L |
| Renal Cysts and Diabetes | | | | |
| <input type="checkbox"/> 776 | HNFB1B DNA Sequencing and Deletion Evaluation (RCAD) | B | 10 mL | L |
| Rickets | | | | |
| <input type="checkbox"/> 857 | Hypophosphatemic Rickets Evaluation (PHEX, FGF23) | B | 10 mL | L |
| <input type="checkbox"/> 855 | PHEX DNA Seq. Test (X-linked Hypophosphatemic Rickets) | B | 10 mL | L |
| <input type="checkbox"/> 856 | FGF23 DNA Sequencing Test (Autosomal Dominant Hypophosphatemic Rickets) | B | 10 mL | L |

Specimen Requirements & Shipping Information

| | |
|----------------------------------|--|
| Specimen Type: | B - Blood |
| Tube Type: | L - Lavender |
| Pediatric Minimum Volume: | 2 mL (for blood tests) |
| Stability: | Hemolysis may compromise DNA recovery and integrity after 48 hrs. It is recommended to ship samples immediately after draw. Samples can be stored for short periods only. Send specimen overnight at room temperature. |
| Shipping: | Send specimen overnight at room temperature. If you have any questions on sample requirements or shipping, contact our client service department at 800-394-4493, extension 2. |

NOTE: Specimen tube(s) must be labeled with two of the following forms of identification: name, date of birth, last four digits of SS#, patient ID no. These same two forms of ID must also be indicated on the test requisition.

Athena Diagnostics Client Service Representatives are available from 8:30am to 6:30pm Eastern Time (U.S.).

International Customers please call

00-1-508-756-2886

or Fax 00-1-610-271-6085



200 Forest Street, 2nd Floor
Marlborough, MA 01752 USA • AthenaDiagnostics.com